Year: 2026
Type: article
Abstract: United States Pharmacopeia (USP), a nonprofit organization that sets safety standards for food, medicine and supplements updated its Chapter 797 standards for the preparation of allergy immunotherapy vials in November 2023. These guidelines impacted facility and personnel qualifications, workflow, and laboratory documentation. We hypothesized adhering to regulations may be financially difficult for allergy practices. To comply, offices must either use mail order prescription facilities or allocate financial resources to purchase a Primary Engineering Control (PEC) Hood, a device used to protect against airborne contaminants, or build-out an Allergenic Extract Compounding Area (AECA), a room specialized for compounding allergens. We performed a comparative analysis to determine financial feasibility of these three scenarios with the support of a Public Service Enterprise Group (PSEG) grant. Of these three options prescription sets were most costly, followed by PEC Hood and AECA. For both PEC Hood and AECA, costs were recouped by the third week of operation. In conclusion, for long term operation, the AECA would be most feasible for small private practice outpatient clinics in regard to overall cost and estimated revenue.
Source: Frontiers in Allergy
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,077
OpenAlex ID: W7123356534